Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Articles published by ClearNote Health

ClearNote Health to Showcase Latest Advancements in Early Cancer Detection Testing at ESMO Congress 2025
From ClearNote Health
Via Business Wire
ClearNote Health Receives In Vitro Diagnostic Approval in United Kingdom for Avantect® Multi-Cancer Detection Test and Avantect® Ovarian Cancer Test
From ClearNote Health
Via Business Wire
ClearNote Health Receives First In Vitro Diagnostic Approval for its Avantect® Pancreatic Cancer Test
From ClearNote Health
Via Business Wire
ClearNote Health Avantect® Pancreatic Cancer Test Enters Patient Enrollment Phase of Groundbreaking UK Study Targeting High-Risk Patients
From ClearNote Health
Via Business Wire
ClearNote Health to Showcase Latest Advancements in Tumor Subtyping and Circulating Tumor Fraction Technologies at AACR Annual Meeting 2025
From ClearNote Health
Via Business Wire
ClearNote Health’s Avantect® Pancreatic Cancer Test Now Available to Health Plan Members Accessing Claritev’s National PPO Networks
From ClearNote Health
Via Business Wire
ClearNote Health Earns Approval for Avantect® Pancreatic Cancer Test from New York State Department of Health
From ClearNote Health
Via Business Wire
ClearNote Health’s Avantect® Multi-Cancer Detection Test Selected as One of Two Noninvasive Blood-Based Technologies for National Cancer Institute’s Vanguard Study
From ClearNote Health
Via Business Wire
ClearNote Health’s Avantect® Test Selected for World’s Largest Study of Pancreatic Cancer Detection in High-Risk Patient Population
From ClearNote Health
Via Business Wire
Avantect Pancreatic Cancer Test Cost-Effective When Used as a Surveillance Tool in High-Risk Patients Newly Diagnosed with Diabetes
From ClearNote Health
Via Business Wire
Avantect Ovarian Cancer Test Receives CPT Code and Preliminary Payment Determination from the Centers for Medicare and Medicaid Services
From ClearNote Health
Via Business Wire
New Data Show ClearNote Health’s Epigenomic Platform Provides a Novel Tissue-Free, Liquid Biopsy-Based Approach to Identify Potential Predictive Biomarker Candidates to Radioligand Therapy Response in Patients With Pancreatic Neuroendocrine Tumors
From ClearNote Health
Via Business Wire
ClearNote Health Announces New Proprietary Approach for Predicting Immunotherapy Treatment Response in Non-Small Cell Lung Cancer Using Only Blood
From ClearNote Health
Via Business Wire
ClearNote Health Announces Collaboration with Bayer to Investigate Drug Treatment Response by Liquid Biopsy in Prostate Cancer
From ClearNote Health
Via Business Wire
ClearNote Health Joins the Pancreatic Cancer Early Detection (PRECEDE) Consortium in New Partnership to Reduce Cancer Mortality
From ClearNote Health
Via Business Wire
Avantect Pancreatic Cancer Test Receives CPT Code and Preliminary Payment Determination from the Centers for Medicare and Medicaid Services
From ClearNote Health
Via Business Wire
Study Validating ClearNote Health’s Avantect Pancreatic Cancer Detection Test Published in the Journal Clinical Gastroenterology and Hepatology
From ClearNote Health
Via Business Wire
ClearNote Health to Present at 41st Annual J.P. Morgan Healthcare Conference
From ClearNote Health
Via Business Wire
Bluestar Genomics Advances to Commercial Phase, Rebrands as ClearNote Health
From ClearNote Health
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.